Fingolimod Hydrochloride

"Fingolimod Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.

Descriptor ID	D000068876
MeSH Number(s)	D02.033.100.700.350 D02.033.455.706.431 D02.092.063.700.350
Concept/Terms	Fingolimod Hydrochloride Fingolimod Hydrochloride Hydrochloride, Fingolimod 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride FTY-720 FTY-720 FTY 720 FTY720 Gilenya Gilenya Gilenia Fingolimod Fingolimod

Below are MeSH descriptors whose meaning is more general than "Fingolimod Hydrochloride".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Alcohols [D02.033]
Amino Alcohols [D02.033.100]
Sphingosine [D02.033.100.700]
Fingolimod Hydrochloride [D02.033.100.700.350]
Glycols [D02.033.455]
Propylene Glycols [D02.033.455.706]
Fingolimod Hydrochloride [D02.033.455.706.431]
Amines [D02.092]
Amino Alcohols [D02.092.063]
Sphingosine [D02.092.063.700]
Fingolimod Hydrochloride [D02.092.063.700.350]

Below are MeSH descriptors whose meaning is related to "Fingolimod Hydrochloride".

Below are MeSH descriptors whose meaning is more specific than "Fingolimod Hydrochloride".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Fingolimod Hydrochloride" by people in this website by year, and whether "Fingolimod Hydrochloride" was a major or minor topic of these publications.

Bar chart showing 13 publications over 9 distinct years, with a maximum of 2 publications in 2011 and 2014 and 2016 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2007	0	1	1
2011	0	2	2
2012	0	1	1
2014	0	2	2
2015	0	1	1
2016	2	0	2
2018	1	0	1
2019	1	0	1
2021	1	1	2

Below are the most recent publications written about "Fingolimod Hydrochloride" by people in Profiles.

Gontika M, Skarlis C, Markoglou N, Evangelopoulos ME, Velonakis G, Chrousos GP, Dalakas M, Stefanis L, Anagnostouli M. Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data. Neurol Sci. 2022 Apr; 43(4):2641-2649.

View in: PubMed
Abrahamowicz AA, Chow EJ, Child DD, Dao A, Morrison ED, Gill SK, Rogers DM, Garvin K. Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod. Neurol Neuroimmunol Neuroinflamm. 2021 05; 8(3).

View in: PubMed
Vicente C, Arriazu E, Mart?nez-Balsalobre E, Peris I, Marcotegui N, Garc?a-Ram?rez P, Pippa R, Rabal O, Oyarz?bal J, Guruceaga E, Pr?sper F, Mateos MC, Cayuela ML, Odero MD. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity. Cancer Lett. 2020 01 01; 468:1-13.

View in: PubMed
Hughes R, Dalakas MC, Merkies I, Latov N, L?ger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurol. 2018 08; 17(8):689-698.

View in: PubMed
Zhang Y, Li X, Ciric B, Ma CG, Gran B, Rostami A, Zhang GX. Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair. Mol Ther. 2017 02 01; 25(2):401-415.

View in: PubMed
Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. Mult Scler Relat Disord. 2016 Nov; 10:204-212.

View in: PubMed
Estella-Hermoso de Mendoza A, Castello-Cros R, Imbuluzqueta E, Cirauqui C, Pippa R, Odero MD, Blanco-Prieto MJ. Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia. J Biomed Nanotechnol. 2015 Apr; 11(4):691-701.

View in: PubMed
Rosini JM, Rajasimhan S, Fellows SE, Nomura JT. Delayed cardiac dysrhythmias after fingolimod administration. Am J Emerg Med. 2015 Jul; 33(7):987.e1-3.

View in: PubMed
Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP, Odero MD. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia. 2014 Sep; 28(9):1915-8.

View in: PubMed
Huggins A, Sergott RC. Gilenya safety update: cardiac and macula. Curr Opin Ophthalmol. 2012 Nov; 23(6):457-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement